保泰松

用途

• General inflammation/pain
• General inflammation/pain
• To reduce pain or pyrexia associated with pleuropneumonia
• General musculoskeletal inflammation
• Adjunctive treatment of colic (to reduce endotoxic effects)
• Adjunctive treatment of laminitis
• Osteoarthritis
• General inflammation/pain
• General inflammation/pain
• General inflammation/pain
• General inflammation/pain
• Analgesia

給藥方式

可能的副作用

• Gastrointestinal and oral erosions/ulcers
• Hypoalbuminemia (especially in foals/ponies)
• Renal papillary necrosis and azotemia
• Sodium and water retention (edema)
• Blood dyscrasias (agranulocytosis, aplastic anemia)
• Hepatotoxicity
• Severe tissue necrosis and sloughing (if injected IM or SC)
• CNS stimulation and seizures (if injected intracarotid)
• Gastrointestinal ulceration and bleeding
• Bone marrow suppression (aplastic anemia, leukopenia)
• Renal papillary necrosis
• Sodium and water retention

注意事項與禁忌

• Known hypersensitivity to phenylbutazone or other NSAIDs
• History of or preexisting hematologic or bone marrow abnormalities
• Preexisting gastrointestinal ulcers
• Food-producing animals (especially female dairy cattle 20 months of age or older)
• Lactating dairy cattle
• Pre-existing gastrointestinal ulceration
• Renal impairment
• Hepatic impairment
• Hematological disorders
• Use in food-producing animals (banned in many jurisdictions)
• Use with extreme caution in foals and ponies due to increased incidence of hypoproteinemia and GI ulceration. Avoid in horses with known or suspected Equine Gastric Ulcer Syndrome (EGUS). Use cautiously in animals with preexisting renal disease or congestive heart failure (CHF) due to potential for sodium/water retention and decreased renal blood flow. May mask clinical signs of lameness in horses. **WARNING:** Do not administer injectable preparations IM or SC as it is highly irritating and causes necrosis/sloughing. Intracarotid injections may cause CNS stimulation and seizures.

藥物相互作用

• Furosemide: Phenylbutazone may antagonize the increased renal blood flow effects caused by furosemide.
• Hepatotoxic Drugs: Concurrent administration may increase the chances of hepatotoxicity developing.
• NSAIDs: Concurrent use increases the potential for adverse GI and renal reactions. (Note: 'Stacking' with ketoprofen shows synergistic toxicity).
• Penicillamine: May increase the risk of hematologic and/or renal adverse reactions.
• Penicillin G: Phenylbutazone may increase the plasma half-life of penicillin G.
• Sulfonamides: Phenylbutazone could potentially displace sulfonamides from plasma proteins, increasing the risk for adverse effects.
• Warfarin: Phenylbutazone could potentially displace warfarin from plasma proteins, increasing the risk for bleeding.
• Corticosteroids: Increased risk of gastrointestinal ulceration
• Other NSAIDs: Increased risk of gastrointestinal ulceration and renal toxicity
• Highly protein-bound drugs (e.g., warfarin): Displacement from plasma proteins leading to increased free drug concentrations

常見問題